# Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update
Ticker: ARVN
Company: Arvinas, Inc.
Source: Arvinas, Inc.
Published: 2026-05-12 11:05 EST
Original Source URL: https://ir.arvinas.com
## Summary

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights

## Article Body
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights
## Recent Company News
- 2026-06-04 12:00 EST — [Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease](https://biopharmsignal.com/news/ARVN/arvinas-joins-the-michael-j-fox-foundation-s-lite-and-ppmi-programs-to-advance-new-therapies-targeting-lrrk2-for-parkinson-s-disease) — Source: Arvinas, Inc.
- 2026-05-29 20:01 EST — [Arvinas to Present at Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ARVN/arvinas-to-present-at-jefferies-global-healthcare-conference) — Source: Arvinas, Inc.
- 2026-05-18 14:30 EST — [Arvinas Employees Give Back During Company-wide Impact Day](https://biopharmsignal.com/news/ARVN/arvinas-employees-give-back-during-company-wide-impact-day) — Source: Arvinas, Inc.
- 2026-05-12 11:05 EST — [Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ARVN/arvinas-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Arvinas, Inc.
- 2026-05-12 11:00 EST — [Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)](https://biopharmsignal.com/news/ARVN/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant) — Source: Arvinas, Inc.
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)